Andreas Evers
32Patents
5h-index
36Co-inventors
65Inventor score
Filing activity: May 22, 2009 → Oct 28, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9181305B2 | Exendin-4 peptide analogues | Emerging Cross-Sectional Technologies | 20 | Active |
| US9750788B2 | Non-acylated exendin-4 peptide analogues | Chemistry; Metallurgy | 10 | Active |
| US9365632B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | Emerging Cross-Sectional Technologies | 6 | Active |
| US9758561B2 | Dual GLP-1/glucagon receptor agonists derived from exendin-4 | Human Necessities | 5 | Active |
| US9745360B2 | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists | Emerging Cross-Sectional Technologies | 5 | Active |
| US8580777B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | Chemistry; Metallurgy | 4 | Active |
| US9751926B2 | Dual GLP-1/GIP receptor agonists | Chemistry; Metallurgy | 3 | Active |
| US9775904B2 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists | Chemistry; Metallurgy | 3 | Active |
| US9126955B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | Chemistry; Metallurgy | 3 | Active |
| US9771406B2 | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 | Chemistry; Metallurgy | 3 | Active |
| US9694053B2 | Dual GLP-1/glucagon receptor agonists | Chemistry; Metallurgy | 3 | Active |
| US8722655B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | Chemistry; Metallurgy | 3 | Active |
| US9789165B2 | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists | Chemistry; Metallurgy | 3 | Active |
| US9309207B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | Chemistry; Metallurgy | 2 | Active |
| US9670261B2 | Functionalized exendin-4 derivatives | Emerging Cross-Sectional Technologies | 2 | Active |
| US10583174B2 | FGF21 compound / GLP-1R agonist combinations with optimized activity ratio | Chemistry; Metallurgy | 2 | Active |
| US10792367B2 | Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid | Chemistry; Metallurgy | 1 | Active |
| US9982029B2 | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists | Human Necessities | 1 | Active |
| US10519211B2 | Compounds as peptidic GLP1/glucagon/GIP receptor agonists | Chemistry; Metallurgy | 1 | Active |
| US10758592B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US11141489B2 | Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid | Chemistry; Metallurgy | 0 | Active |
| US10806797B2 | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate | Human Necessities | 0 | Active |
| US9932381B2 | Exendin-4 derivatives as selective glucagon receptor agonists | Human Necessities | 0 | Active |
| US9221784B2 | Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists | Chemistry; Metallurgy | 0 | Active |
| US11046743B2 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.